10 Best Low Volatility Investments in December 2025

Page 8 of 10

3. Johnson & Johnson (NYSE:JNJ)

Beta Value: 0.34

Dividend Yield: 2.51%

Number of Hedge Fund Holders: 103

Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim reaffirmed a Buy rating and $206 price target on healthcare giant Johnson & Johnson (NYSE:JNJ), citing favorable clinical trial findings for its multiple myeloma therapy. The firm noted preliminary data from the MajesTEC-3 trial, which combines Johnson & Johnson (NYSE:JNJ)’s Tecvayli and Darzalex medications, as “overwhelmingly positive” and potentially creating a novel standard of treatment for relapsed/refractory multiple myeloma patients.

In comparison to current therapy standard’s, the Tecvayli-Darzalex combination considerably enhanced both progression-free survival and overall survival. Previous Phase 2 data also demonstrated encouraging outcomes, with all evaluable patients achieving a 100% overall response rate with little residual disease negativity.

Guggenheim believes that the data presentation at the upcoming annual American Society of Hematology Meeting in December will highlight a “paradigm shift” in multiple myeloma treatment, potentially boosting Tecvayli’s market share.

Johnson & Johnson (NYSE:JNJ) is a diversified healthcare company. It operates through three main segments: Innovative Medicine, MedTech, and Consumer Health. Its products range from pharmaceuticals and medical devices to widely recognized consumer brands.

Page 8 of 10